Evidence map›Paper›PMID 42326768›Full record

ArticlemedRxiv : the preprint server for health sciences2026

A hierarchical clinical fusion transformer model for personalized opioid treatment: Development and validation in diabetic surgical patients.

Behzad Naderalvojoud, Brian J Sutjiadi, Arman Koul, Catherine Curtin, Olivier Gevaert, Tina Hernandez-Boussard

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Behzad NaderalvojoudDepartment of Medicine, Stanford University, Stanford, CA 94305, United States.
Brian J SutjiadiDepartment of Medicine, Stanford University, Stanford, CA 94305, United States.
Arman KoulDepartment of Medicine, Stanford University, Stanford, CA 94305, United States.
Catherine CurtinDepartment of Surgery, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, United States.
Olivier GevaertDepartment of Medicine, Stanford University, Stanford, CA 94305, United States.
Tina Hernandez-BoussardDepartment of Medicine, Stanford University, Stanford, CA 94305, United States.

Funding

Advancing Knowledge Discovery for Postoperative Pain ManagementR01LM013362 · NLM · STANFORD UNIVERSITY · PI HERNANDEZ-BOUSSARD, TINA · 2019 to 2023
$3.2M
NLM NIH HHS R01 LM013362
6 · The paper itself

Abstract

Background: Machine learning (ML) models are increasingly used to predict adverse outcomes after surgery. However, most rely on static patient characteristics (e.g., age, comorbidities) and overlook clinician-controlled treatment decisions that can be actively modified at the point of care. Discharge opioid prescribing is a key modifiable, clinician-controlled decision, yet optimizing prescribing choices across multiple adverse outcomes remains underexplored in predictive modeling. This study addresses that gap by introducing a novel ML framework that explicitly separates fixed patient risk factors from modifiable prescribing options to support personalized, risk-informed opioid prescribing decisions. Methods: We developed the Hierarchical Clinical Fusion Transformer (HCF-Transformer), an ML model designed to estimate patient-specific risks across four postoperative outcomes: prolonged opioid use (POU), chronic pain (CP), 30-day readmission, and opioid-associated outcomes (OAO). The model constructs patient risk profiles from fixed, non-modifiable baseline factors, followed by a transformer layer. Clinician-controllable discharge opioid regimens are modeled as alternative intervention candidates and fused with the fixed risk representation through a clinical fusion mechanism, enabling assessment and ranking based on predicted risks. A Total Relative Risk (TRR) metric, calibrated to each outcome prediction threshold, guides the recommendation process. We evaluated the model in diabetic surgical patients, a common high-risk population. Results: The study included 157,853 unique diabetic surgical patients, with outcome prevalences ranging from 47.2% (POU) to 1.8% (OAO). The HCF-Transformer achieved the highest AUROCs, 0.798 for POU, 0.712 for 30-day readmission, 0.808 for CP, and 0.922 for OAO, outperforming Random Forest, FT-Transformer, and ResNet-based models. Compared to these baselines, HCF-Transformer generated more stable and discriminative risk estimates and demonstrated significant variation in TRR scores across discharge opioid options (ANOVA Conclusions: The HCF-Transformer introduces a novel hierarchical fusion approach to optimize opioid prescribing by integrating static patient risk profiles with modifiable discharge options. Using transformer-based modeling and a quantifiable TRR metric, the model delivers personalized, risk-aware recommendations. This approach enables data-driven opioid prescribing tailored to individual risk and has the potential to improve postoperative outcomes in high-risk populations. Our findings demonstrate that integrating modifiable factors with structured risk profiles through a transformer-based fusion architecture can enhance decision-support systems, paving the way for more actionable and personalized AI in healthcare.

Indexed as

Diabetic surgical patientsHCF-TransformerMachine learningPersonalized opioid prescribingPostoperative opioid use

Identifiers

PMID42326768
PMCPMC13278198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.